Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Optimizing timing of vaccinations and chemotherapy

Eva Segelov • 5 Jun 2022
ASCO 2022
General
SerOzNET

Eva Segelov, MBBS, PhD, FRACP, Monash University, Melbourne, Australia, discusses data collected from the prospective, observational study, SerOzNET (ACTRN12621001004853) study on whether patients were on treatment with steroids at the time of receiving the COVD-19 vaccine to aid in optimizing the timing of vaccinations and chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Eva Segelov

1:13
Improving the care of patients with cancer in a “post-COVID” world
Eva Segelov • 5 Jun 2022
4:05
SerOzNET study: SARS-CoV-2 post-vaccine surveillance study in Australian patients with cancer
Eva Segelov • 5 Jun 2022

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals